Clinician-Patient Dialogue About Preventive Chronic Migraine Treatment

por Blumenfeld, Andrew M.
Publicado 2020

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine

por Ailani, Jessica, Blumenfeld, Andrew M.
Publicado 2021

Reproducible features of small RNAs in C. elegans reveal NU RNAs and provide insights into 22G RNAs and 26G RNAs

por Blumenfeld, Andrew L., Jose, Antony M.
Publicado 2016

Response to “Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice”

por Blumenfeld, Andrew M., Silberstein, Stephen D.
Publicado 2020

Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study

por Blumenfeld, Andrew M., Boyd, James P.
Publicado 2022

Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotul...

por Blumenfeld, Andrew M., Aurora, Sheena K., Laranjo, Karen, Papapetropoulos, Spyros
Publicado 2015

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

por Blumenfeld, Andrew, Ettrup, Anders, Hirman, Joe, Ebert, Bjarke, Cady, Roger
Publicado 2022

Practical Insights on the Identification and Management of Patients with Chronic Migraine

por Blumenfeld, Andrew, Dueland, Aud Nome, Evers, Stefan, Jenkins, Bronwyn, Martelletti, Paolo, Sommer, Katherine
Publicado 2022

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience

por Blumenfeld, Andrew, Tepper, Stewart J., Khanna, Rashna, Doty, Erin, Vincent, Maurice, Miller, Sheila I.
Publicado 2023

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

por Blumenfeld, Andrew M., Stark, Richard J., Freeman, Marshall C., Orejudos, Amelia, Manack Adams, Aubrey
Publicado 2018

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

por Burstein, Rami, Blumenfeld, Andrew M., Silberstein, Stephen D., Manack Adams, Aubrey, Brin, Mitchell F.
Publicado 2020

Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor

por Blumenfeld, Andrew, Durham, Paul L., Feoktistov, Alexander, Hay, Debbie L., Russo, Andrew F., Turner, Ira
Publicado 2021

Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review

por Blumenfeld, Andrew M., Kaur, Gavneet, Mahajan, Anadi, Shukla, Hemlata, Sommer, Katherine, Tung, Amy, Knievel, Kerry L.
Publicado 2022

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

por Blumenfeld, Andrew M., Patel, Atul T., Turner, Ira M., Mullin, Kathleen B., Manack Adams, Aubrey, Rothrock, John F.
Publicado 2020

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials

por Blumenfeld, Andrew M., Knievel, Kerry, Manack Adams, Aubrey, Severt, Lawrence, Butler, Matthew, Lai, Hongxin, Dodick, David W.
Publicado 2021

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes

por Blumenfeld, Andrew M., Silberstein, Stephen D., Dodick, David W., Aurora, Sheena K., Brin, Mitchell F., Binder, William J.
Publicado 2017

Lasmiditan mechanism of action – review of a selective 5-HT(1F) agonist

por Clemow, David B., Johnson, Kirk W., Hochstetler, Helen M., Ossipov, Michael H., Hake, Ann M., Blumenfeld, Andrew M.
Publicado 2020

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

por Blumenfeld, Andrew M., Frishberg, Benjamin M., Schim, Jack D., Iannone, Ashley, Schneider, Gary, Yedigarova, Larisa, Manack Adams, Aubrey
Publicado 2021

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials

por Ailani, Jessica, Kuruppu, Dulanji K., Rettiganti, Mallikarjuna, Oakes, Tina, Schroeder, Krista, Wietecha, Linda, Port, Martha, Blumenfeld, Andrew M.
Publicado 2022

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine

por Rothrock, John F., Adams, Aubrey Manack, Lipton, Richard B., Silberstein, Stephen D., Jo, Esther, Zhao, Xiang, Blumenfeld, Andrew M.
Publicado 2019